GlobeNewswire: CymaBay Therapeutics, Inc. Contains the last 10 of 237 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:43:01ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/04/2839523/0/en/CymaBay-Announces-European-Medicines-Agency-Accepts-for-Review-the-Marketing-Authorization-Application-for-Seladelpar-for-the-Treatment-of-Primary-Biliary-Cholangitis.html?f=22&fvtc=4&fvtv=27011CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis2024-03-04T13:00:00Z<![CDATA[MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA]]>https://www.globenewswire.com/news-release/2024/02/28/2837495/0/en/CymaBay-Reports-Fourth-Quarter-and-Year-Ended-December-31-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=27011CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update2024-02-28T21:45:25Z<![CDATA[Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.]]>https://www.globenewswire.com/news-release/2024/02/20/2832269/0/en/CymaBay-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27011CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-02-20T21:05:00Z<![CDATA[NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees on February 16, 2024 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 99,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grants.]]>https://www.globenewswire.com/news-release/2024/01/31/2821052/0/en/CymaBay-Therapeutics-to-Participate-in-Upcoming-Investment-Conferences.html?f=22&fvtc=4&fvtv=27011CymaBay Therapeutics to Participate in Upcoming Investment Conferences2024-01-31T13:00:00Z<![CDATA[NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY, Raymond James & Associates’ 45th Annual Institutional Investors Conference, March 4-6, in Orlando, Florida, and Leerink Partners Global Biopharma Conference, March 11-13, in Miami, Florida.]]>https://www.globenewswire.com/news-release/2024/01/16/2810337/0/en/CymaBay-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27011CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-01-16T21:28:43Z<![CDATA[NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to two employees on January 12, 2024 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 52,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grants.]]>https://www.globenewswire.com/news-release/2024/01/02/2802612/0/en/CymaBay-Therapeutics-to-Present-at-the-42nd-Annual-JP-Morgan-Healthcare-Conference-2024.html?f=22&fvtc=4&fvtv=27011CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 20242024-01-02T13:00:00Z<![CDATA[NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.]]>https://www.globenewswire.com/news-release/2023/12/18/2798129/0/en/CymaBay-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27011CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-12-18T21:05:00Z<![CDATA[NEWARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to four employees on December 15, 2023 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 176,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grants.]]>https://www.globenewswire.com/news-release/2023/11/17/2782736/0/en/CymaBay-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27011CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-11-17T21:15:00Z<![CDATA[NEWARK, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to five employees on November 15, 2023 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymaBay approved the grant of non-qualified stock options to purchase an aggregate of 182,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grants.]]>https://www.globenewswire.com/news-release/2023/11/07/2775572/0/en/CymaBay-Reports-Third-Quarter-and-Nine-Months-Ended-September-30-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=27011CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update2023-11-07T21:04:00Z<![CDATA[Announced top-line results from RESPONSE Phase 3 study in PBC where seladelpar met the primary and two key secondary endpoints with high statistical significance.]]>https://www.globenewswire.com/news-release/2023/11/06/2774054/0/en/CymaBay-Therapeutics-to-Present-at-Upcoming-Investment-Conferences.html?f=22&fvtc=4&fvtv=27011CymaBay Therapeutics to Present at Upcoming Investment Conferences2023-11-06T13:00:00Z<![CDATA[NEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9th in Miami Beach, FL, the Piper Sandler 35th Annual Healthcare Conference, November 28-30th, in New York, NY, and the Evercore ISI 6th Annual HealthCONx Conference, November 28-30th, in Miami, Florida.]]>